Quest Diagnostics Reports the Acquisition of PathAI Diagnostics to Enhance Cancer Diagnosis
Shots:
- Quest & PathAI have entered into a multi-faceted agreement to expedite digital & AI pathology adoption enhancing cancer & other disease diagnosis
- Quest will acquire PathAI's arm offering anatomic & digital pathology lab services. Post-acquisition, PathAI’s digitized lab in Memphis will transform into Quest's AI & digital R&D center, supporting its AmeriPath & Dermpath Diagnostics. The transaction will conclude in Q2’24
- Under a separate agreement, Quest will license PathAI's AISight digital pathology image management system strengthening its pathology labs & customer sites in the US with becoming preferred provider for PathAI's biopharma clinical lab services; pursue opportunities on algorithm product development using Quest's pathology expertise
Ref: Quest Diagnostics | Image: Quest Diagnostics
Related News:- Quest Diagnostic Receives the US FDA's First EUA for Sample Pooling in COVID-19
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
